Nav: Home

4/26 Workshop on COAs in Cancer Clinical Trials

April 21, 2016

The Food and Drug Administration's (FDA) Office of Hematology and Oncology Products, in co-sponsorship with the Critical Path Institute's (C-Path) Patient-Reported Outcome (PRO) Consortium, is holding a public meeting titled "Workshop on Clinical Outcome Assessments (COAs) in Cancer Clinical Trials" on Tuesday, April 26, 7:30am-5pm. The purpose of the workshop is to provide a forum for collaborative multidisciplinary discussion to identify best practices for the use of PRO measures in oncology drug development. During this workshop, a broad array of international stakeholders involved in oncology drug development, regulation, utilization, and reimbursement will provide perspectives on the current approaches to PRO assessment in oncology trials, explore the utility of information derived from existing PRO measures, and identify potential ways to improve alignment and strategic use of PRO measures to support oncology drug development and better inform treatment decisions. The workshop will include focused discussions on important core patient-centered concepts, including patient-reported disease-related symptoms, symptomatic adverse events,and physical function. This workshop will include panelists and speakers from FDA, international regulatory agencies and health technology assessment bodies, domestic payers, academia, pharmaceutical industry, and patient advocacy groups.

The goals of this workshop are:

·To engage with international stakeholders in cancer drug development, approval, reimbursement, and utilization to gain a better understanding of how patient-centered data is used across these different groups

·To review common PRO assessment strategies and discuss new and existing PRO measurement tools available to assess the patient experience in cancer clinical trials

· To obtain stakeholder feedback on a proposed modular PRO measurement approach in cancer clinical trials that better integrates new measurement tools and more closely adheres to U.S. regulatory requirements for product labeling

·To review available tools and approaches to the assessment and analysis of patient-reported physical function, an important component of health-related quality of life in cancer patients undergoing therapy
-end-


The Critical Path Institute (C-Path)

Related Health Articles:

Health records pin broad set of health risks on genetic premutation
Researchers from the University of Wisconsin-Madison and Marshfield Clinic have found that there may be a much broader health risk to carriers of the FMR1 premutation, with potentially dozens of clinical conditions that can be ascribed directly to carrying it.
Attitudes about health affect how older adults engage with negative health news
To get older adults to pay attention to important health information, preface it with the good news about their health.
Geographic and health system correlates of interprofessional oral health practice
In the current issue of Family Medicine and Community Health (Volume 6, Number 2, 2018, pp.
Bloomberg era's emphasis on 'health in all policies' improved New Yorkers' heart health
From 2002 to 2013, New York City implemented a series of policies prioritizing the public's health in areas beyond traditional healthcare policies and illustrated the potential to reduce cardiovascular disease risk.
Youth consider mobile health units a safe place for sexual health services
Mobile health units bring important medical services to communities across the country.
More Health News and Health Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...